After a year of follow-up, patients with STEMI who received thrombus aspiration during PCI had similar results in the primary outcome of cardiovascular death, recurrent MI, cardiogenic shock or class IV heart failure compared with patients undergoing PCI alone, according to a prospective, randomized trial.

Providing ranolazine to patients with chronic angina and incomplete revascularization after undergoing PCI did not reduce the composite end point of ischemia-driven revascularization or hospitalization without revascularization, according to a multicenter, randomized, double-blind, placebo-controlled study.

More than a year’s worth of real world data in more than 6,000 patients showed that all-cause mortality rates and stroke at 30 days with Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system were comparable with findings in the pivotal trial that led to the device’s approval.

Patients undergoing PCI who received a second-generation drug-eluting absorbable metal scaffold had favorable angiographic and clinical outcomes after six months, according to the first in-man study of the device.

The results of the ABSORB III trial were within the prespecified margin for noninferiority with regards to the primary end point of target-lesion failure, which researchers defined as cardiac death, target-vessel MI or ischemia-driven target-lesion revascularization.

Within two years following PCIs, 13.3 percent of subsequent scheduled noncardiac surgical procedures were cancelled, according to an analysis of all PCIs performed at the Veterans Affairs (VA) Healthcare System from fiscal year 2000 to 2010.

From Oct. 11 to 15, leaders in interventional cardiovascular medicine will gather in San Francisco for the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Cardinal Health completed its acquisition of Johnson and Johnson’s Cordis business on Oct. 4 for $1.944 billion, seven months after Cardinal Health announced its offer.